Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

AI-derived body composition analysis reveals muscle volume and metformin-associated adipose effects and the obesity paradox in non-small cell lung cancer

Wang X., Hata A., Wada N., Song J., Fukuda T., Nakamura Y.

Retrospective Study with a reported sample of 93 on Hip, Systemic / IV, published in EBioMedicine (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
EBioMedicine (2025)
Reported sample size
93
Source database
Europe PMC
PMID
41166991
PMCID
PMC12613069
DOI
10.1016/j.ebiom.2025.105995
Citations
2

Abstract (original English)

Background Body composition is emerging as a prognostic factor in cancer, with metformin showing potential antitumour effects in patients with obesity and non-small cell lung cancer (NSCLC). We aimed to determine which specific body composition components drive survival differences in different patient subgroups and explore underlying molecular mechanisms. Methods In this retrospective cohort study, we analysed 1275 patients with confirmed NSCLC diagnosis and available chest CT imaging for body composition analysis at the Massachusetts General Hospital. Six body composition parameters (muscle density and volume, visceral adipose tissue [VAT], subcutaneous adipose tissue [SAT], VAT/SAT ratio, and intramuscular adipose tissue [IMAT]) were quantified using validated CNN-based segmentation algorithms from baseline CT scans. The primary outcome was overall survival (OS), assessed from diagnosis until death or last follow-up. Associations with OS were analysed using multivariable Cox proportional hazards model, followed by subgroup analyses by sex, BMI, diabetes, and metformin use. Circulating cytokine levels (n = 93) and oncogenic driver mutations (n = 646) from the imaging cohort and comprehensive tumour mutation profiles from an independent Memorial Sloan Kettering Cancer Center cohort (n = 5363) were analysed for mechanistic insights. Findings Muscle volume demonstrated a dose-re

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Muscle, SkeletalAdipose TissueHumansCarcinoma, Non-Small-Cell LungLung NeoplasmsObesityMetforminHypoglycemic AgentsTomography, X-Ray ComputedPrognosis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research